The DOI matches its Crossref record; 92 of the 92 references it cites were found in a registry or an index.
Cytogenetic and Molecular Genetic Evolution of Chronic Myeloid Leukemia
Abstract
Chronic myeloid leukemia (CML) is genetically characterized by the presence of the reciprocal translocation t(9;22)(q34;q11), resulting in a BCR/ABL gene fusion on the derivative chromosome 22 called the Philadelphia (Ph) chromosome. In 2–10% of the cases, this chimeric gene is generated by variant rearrangements, involving 9q34, 22q11, and one or several other genomic regions. All chromosomes have been described as participating in these variants, but there is a marked breakpoint clustering to chromosome bands 1p36, 3p21, 5q13, 6p21, 9q22, 11q13, 12p13, 17p13, 17q21, 17q25, 19q13, 21q22, 22q12, and 22q13. Despite their genetically complex nature, available data indicate that variant rearrangements do not confer any specific phenotypic or prognostic impact as compared to CML with a standard Ph chromosome. In most instances, the t(9;22), or a variant thereof, is the sole chromosomal anomaly during the chronic phase (CP) of the disease, whereas additional genetic changes are demonstrable in 60–80% of cases in blast crisis (BC). The secondary chromosomal aberrations are clearly nonrandom, with the most common chromosomal abnormalities being +8 (34% of cases with additional changes), +Ph (30%), i(17q) (20%), +19 (13%), –Y (8% of males), +21 (7%), +17 (5%), and monosomy 7 (5%). We suggest that all these aberrations, occurring in >5% of CML with secondary changes, should be denoted major route abnormalities. Chromosome segments often involved in structural rearrangements include 1q, 3q21, 3q26, 7p, 9p, 11q23, 12p13, 13q11–14, 17p11, 17q10, 21q22, and 22q10. No clear-cut differences as regards type and prevalence of additional aberrations seem to exist between CML with standard t(9;22) and CML with variants, except for slightly lower frequencies of the most common changes in the latter group. The temporal order of the secondary changes varies, but the preferred pathway appears to start with i(17q), followed by +8 and +Ph, and then +19. Molecular genetic abnormalities preceding, or occurring during, BC include overexpression of the BCR/ABL transcript, upregulation of the EVI1 gene, increased telomerase activity, and mutations of the tumor suppressor genes RB1, TP53, and CDKN2A. The cytogenetic evolution patterns vary significantly in relation to treatment given during CP. For example, +8 is more common after busulfan than hydroxyurea therapy, and the secondary changes seen after interferon-alpha treatment or bone marrow transplantation are often unusual, seemingly random, and occasionally transient. Apart from the strong phenotypic impact of addition of acute myeloid leukemia/myelodysplasia-associated translocations and inversions, such as inv(3)(q21q26), t(3;21)(q26;q22), and t(15;17)(q22;q12–21), in CML BC, only a few significant differences between myeloid and lymphoid BC are discerned, with i(17q) and TP53 mutations being more common in myeloid BC and monosomy 7, hypodiploidy, and CDKN2A deletions being more frequent in lymphoid BC. The prognostic significance of the secondary genetic changes is not uniform, although abnormalities involving chromosome 17, e.g., i(17q), have repeatedly been shown to be ominous. However, the clinical impact of additional cytogenetic and molecular genetic aberrations is most likely modified by the treatment modalities used.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
ROWLEY, J. D. (1973) · Nature · doi:10.1038/243290a0 · Cited by 4,291
Clinical Resistance to STI-571 Cancer Therapy Caused by BCR-ABL Gene Mutation or Amplification
Gorre, M. E., Mohammed, M., Ellwood, K., Hsu, N., Paquette, R., Rao, P. N., & Sawyers, C. L. (2001) · Science · doi:10.1126/science.1062538 · Cited by 3,104 · cited 1×
“Summarizing the secondary abnormalities in IFN-treated CML cases (table 3 ), it becomes clear that the incidences of p8, pPh, i(17q), p19, p21, and p17 are lower in the IFN-treated group compared to patients treated with Bu and/or Hy. Furthermore, and similar to the post-BMT group, the frequencies of secondary balance…”
ResultA minute chromosome in human chronic granulocytic leukemia
Nowell̀, P. C. (1960) · Science · Cited by 2,269
Fused transcript of abl and bcr genes in chronic myelogenous leukaemia
Shtivelman, E., Lifshitz, B., Gale, R. P., & Canaani, E. (1985) · Nature · doi:10.1038/315550a0 · Cited by 1,611
Chromosome Studies on Normal and Leukemic Human Leukocytes
(1960) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/25.1.85 · Cited by 1,069
Structural organization of the bcr gene and its role in the Ph′ translocation
Heisterkamp, N., Stam, K., Groffen, J., de Klein, A., & Grosveld, G. (1985) · Nature · doi:10.1038/315758a0 · Cited by 882
Clonal origin of chronic myelocytic leukemia in man.
Fialkow, P. J., Gartler, S. M., & Yoshida, A. (1967) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.58.4.1468 · Cited by 525
Drexler, H. (1998) · Leukemia · doi:10.1038/sj.leu.2401043 · Cited by 426
Recurrent chromosome aberrations in cancer
Mitelman, F. (2000) · Mutation Research/Reviews in Mutation Research · doi:10.1016/s1383-5742(00)00006-5 · Cited by 346
Self-citationMitani, K., Ogawa, S., Tanaka, T., Miyoshi, H., Kurokawa, M., Mano, H., Yazaki, Y., Ohki, M., & Hirai, H. (1994) · The EMBO Journal · doi:10.1002/j.1460-2075.1994.tb06288.x · Cited by 325
Cited by
The impact of translocations and gene fusions on cancer causation
Mitelman, F., Johansson, B., & Mertens, F. (2007) · Nature Reviews Cancer · doi:10.1038/nrc2091 · Cited by 1,400
Self-citationA Phase 2 Trial of Ponatinib in Philadelphia Chromosome–Positive Leukemias
Cortes, J. E., Kim, D.-W., Pinilla-Ibarz, J., le Coutre, P., Paquette, R., Chuah, C., Nicolini, F. E., Apperley, J. F., Khoury, H. J., Talpaz, M., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1306494 · Cited by 1,142
Ott, M. G., Schmidt, M., Schwarzwaelder, K., Stein, S., Siler, U., Koehl, U., Glimm, H., Kühlcke, K., Schilz, A., Kunkel, H., et al. (2006) · Nature Medicine · doi:10.1038/nm1393 · Cited by 1,051
Chronic Myeloid Leukemia — Advances in Biology and New Approaches to Treatment
Goldman, J. M., & Melo, J. V. (2003) · New England Journal of Medicine · doi:10.1056/nejmra020777 · Cited by 950
Molecular biology of bcr-abl1–positive chronic myeloid leukemia
Quintás-Cardama, A., & Cortes, J. (2009) · Blood · doi:10.1182/blood-2008-03-144790 · Cited by 745
Chronic myeloid leukaemia as a model of disease evolution in human cancer
Melo, J. V., & Barnes, D. J. (2007) · Nature Reviews Cancer · doi:10.1038/nrc2147 · Cited by 623
The biology of CML blast crisis
Calabretta, B., & Perrotti, D. (2004) · Blood · doi:10.1182/blood-2003-12-4111 · Cited by 592
Response and Resistance to BCR-ABL1-Targeted Therapies
Braun, T. P., Eide, C. A., & Druker, B. J. (2020) · Cancer Cell · doi:10.1016/j.ccell.2020.03.006 · Cited by 483
Chronic myeloid leukemia: mechanisms of blastic transformation
Perrotti, D., Jamieson, C., Goldman, J., & Skorski, T. (2010) · Journal of Clinical Investigation · doi:10.1172/jci41246 · Cited by 397
Specific Targeted Therapy of Chronic Myelogenous Leukemia with Imatinib
Deininger, M. W. N., & Druker, B. J. (2003) · Pharmacological Reviews · doi:10.1124/pr.55.3.4 · Cited by 365
Molecular Signatures of Proliferation and Quiescence in Hematopoietic Stem Cells
Venezia, T. A., Merchant, A. A., Ramos, C. A., Whitehouse, N. L., Young, A. S., Shaw, C. A., & Goodell, M. A. (2004) · PLoS Biology · doi:10.1371/journal.pbio.0020301 · Cited by 362
Hehlmann, R. (2012) · Blood · doi:10.1182/blood-2012-03-380147 · Cited by 273
Milojkovic, D., & Apperley, J. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-1068 · Cited by 265
Myc Roles in Hematopoiesis and Leukemia
Delgado, M. D., & Leon, J. (2010) · Genes & Cancer · doi:10.1177/1947601910377495 · Cited by 255
Wang, W., Cortes, J. E., Tang, G., Khoury, J. D., Wang, S., Bueso-Ramos, C. E., DiGiuseppe, J. A., Chen, Z., Kantarjian, H. M., Medeiros, L. J., et al. (2016) · Blood · doi:10.1182/blood-2016-01-690230 · Cited by 198
Laying the foundation for genomically-based risk assessment in chronic myeloid leukemia
on behalf of the International CML Foundation Genomics Alliance, Branford, S., Kim, D. D. H., Apperley, J. F., Eide, C. A., Mustjoki, S., Ong, S. T., Nteliopoulos, G., Ernst, T., Chuah, C., et al. (2019) · Leukemia · doi:10.1038/s41375-019-0512-y · Cited by 149
High-risk additional chromosomal abnormalities at low blast counts herald death by CML
Hehlmann, R., Voskanyan, A., Lauseker, M., Pfirrmann, M., Kalmanti, L., Rinaldetti, S., Kohlbrenner, K., Haferlach, C., Schlegelberger, B., Fabarius, A., et al. (2020) · Leukemia · doi:10.1038/s41375-020-0826-9 · Cited by 91
Albajar, M., Gómez-Casares, M. T., Llorca, J., Mauleon, I., Vaqué, J. P., Acosta, J. C., Bermúdez, A., Donato, N., Delgado, M. D., & León, J. (2011) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-10-0356 · Cited by 62
Clark, R. E., Apperley, J. F., Copland, M., & Cicconi, S. (2021) · Blood Advances · doi:10.1182/bloodadvances.2020003570 · Cited by 53
“The most common new lesions include trisomy 8, an additional Ph translocation, isochromosome 17q, and trisomy 19.(1-3) However, the prognostic significance at chronic phase diagnosis of these 4 “major route” lesions for disease progression is less clear.”
BackgroundMagistroni, V., Mauri, M., D’Aliberti, D., Mezzatesta, C., Crespiatico, I., Nava, M., Fontana, D., Sharma, N., Parker, W., Schreiber, A., et al. (2019) · Haematologica · doi:10.3324/haematol.2017.179937 · Cited by 29
Impact of emerging ACA on survival in chronic myeloid leukemia (CML)
Hehlmann, R., Lauseker, M., Voskanyan, A., Fabarius, A., Haferlach, C., Hochhaus, A., & Saußele, S. (2022) · Leukemia · doi:10.1038/s41375-022-01681-3 · Cited by 13
Chronic phase CML with sole P190 (e1a2) BCR::ABL1: long-term outcome among ten consecutive cases
Abdelmagid, M. G., Litzow, M. R., McCullough, K. B., Gangat, N., Pardanani, A., Murthy, H. S., Foran, J. M., Ketterling, R. P., Viswanatha, D., Begna, K. H., et al. (2022) · Blood Cancer Journal · doi:10.1038/s41408-022-00696-4 · Cited by 13
Claudiani, S., Chee, L., Fernando, F., Brown, L., Achandira, U. M., Khan, A., Rothwell, K., Hayden, C., Koutsavlis, I., Hannah, G., et al. (2024) · American Journal of Hematology · doi:10.1002/ajh.27278 · Cited by 4
Metadata
- Authors
- Johansson, B., Fioretos, T., & Mitelman, F.
- Venue
- Acta Haematologica
- Publisher
- S. Karger AG
- Published
- 2002
- Volume
- 107
- Issue
- 2
- Pages
- 76-94
- ISSN
- 0001-5792 (ISSN-L)
- 1421-9662
- OpenAlex
- W2038538605
- Cited by
- 454
- References
- 92
- FWCI
- 9.25
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.